First patient treated with chemical renal denervation in Peregrine Study

267

Ablative Solutions has announced that the first patient in the Peregrine Study has been treated with company’s the investigational Peregrine system, which delivers agents directly to the sympathetic-nerve-laden peri-adventitial area of the renal artery to perform chemical neurolysis. Wojtek Wojakowski is the principal investigator of the study, and the patient has now been discharged from the hospital.

A press release reports that the Peregrine Study is currently enrolling patients at two of the hospitals in The American Heart of Poland (AHP) Group. Pawel Buszman, head of AHP, says, “We are pleased to be on the forefront in evaluating the third generation of device-based therapy to address the treatment of severe hypertension. This is a significant health issue in Poland and throughout Europe, since many patients face serious health complications because they have limited options to manage their hypertension.”


Tim Fischell, chief executive officer of Ablative Solutions, comments: “We are very pleased to have initiated the Peregrine Study. We believe that a safe, reproducible, easy to use and more targeted denervation technology with limited pain to the patients will be more effective than energy-based catheter approaches in mitigating overactive sympathetic nerves. Early experience with surgical sympathectomy has demonstrated that effective interruption of these nerves had a beneficial effect on blood pressure. We hope that chemical neurolysis will provide a minimally invasive approach that builds upon some of the early successes of renal denervation, while avoiding many of pitfalls encountered by energy-based systems.”


According to the press release, the Peregrine Study will be expanded to other European clinical sites to secure CE-mark and to enable additional cardiologists to evaluate chemical neurolysis using the Peregrine System in their patients suffering from hypertension.